(VIANEWS) - CVB Financial Corporation (CVBF), TTM Technologies (TTMI), Vertex Pharmaceuticals (VRTX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. CVB Financial Corporation (CVBF)
23.5% sales growth and 11.01% return on equity
CVB Financial Corp. is a bank holding firm for Citizens Business Bank. This state-chartered bank provides financial and banking services to individuals and small businesses. It offers checking, saving, money market and time certificates for deposit products for personal and business accounts. The federal tax depository serves business customers. The company also offers commercial loans products that include lines of credits and other working capital financing. It also has letters of credit. Loans to fund the operations of wholesale dairy farms, cattle feeders and livestock raisers. It offers specialized services such as merchant card processing, cash flow monitoring, automated pick-up, delivery and payroll services. Remote deposit capture, electronic money transfers, wires, clearinghouse and online account access are some of the services offered by the company. It also offers trust services via its CitizensTrust Division. These include fiduciary, mutual fund, annuities and 401(k), plans as well as individual investment accounts. The company had 57 branches in Los Angeles County and Orange County as well as San Diego County and Ventura County. One loan production office was located in Modesto and three trust offices were located in Ontario and Newport Beach. CVB Financial Corp. was established in 1974. It is located in Ontario, California.
Earnings per Share
CVB Financial Corporation's trailing twelve-month EPS is $1.55.
PE Ratio
CVB Financial Corporation's trailing 12-month price-earnings ratio is 18.28. The purchaser of the shares is therefore investing $18.28 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 11.01%.Sales Growth
CVB Financial Corporation has a 35.2% quarter-over-quarter sales increase and 23.5% in the following.
Volume
CVB Financial Corporation's latest reported volume is 131462, which is 79.32% lower than its average volume (635884).
2. TTM Technologies (TTMI)
10.7% sales growth and 6.49% return on equity
TTM Technologies, Inc., along with its subsidiaries, produces and sells worldwide printed circuit boards (PCBs). The company operates segments for RF&S Components and PCB. It offers a variety of products including radio-frequency components and conventional PCBs. The company also makes printed circuits using heavy copper cores. It also offers a variety of services including PCB layout design and simulation, testing and turnaround, as well as design for manufacturing. It serves electronic manufacturing service companies and original equipment makers that specialize in aerospace, defense, computing and automotive components. TTM Technologies, Inc., was founded in 1978. It is located in Santa Ana, California.
Earnings Per Share
As for profitability, TTM Technologies has a trailing twelve months EPS of $0.91.
PE Ratio
TTM Technologies has a trailing twelve months price to earnings ratio of 16.87. Meaning, the purchaser of the share is investing $16.87 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.49%.Yearly Top and Bottom Value
TTM Technologies's stock is valued at $15.35 at 05:30 EST, way under its 52-week high of $17.49 and way higher than its 52-week low of $9.76.
3. Vertex Pharmaceuticals (VRTX)
9.7% sales growth and 30.24% return on equity
Vertex Pharmaceuticals Incorporated is a biotechnology firm that develops and markets therapies to treat cystic fibrosis. SYMDEKO/SYMKEVI and ORKAMBI are available to patients suffering from cystic fibrosis. TRIKAFTA is for patients 6 and older with CF who possess at least one F508del mutation. VX-864 is being developed for AAT deficiency treatment and is currently in Phase 2. Clinical trial. VX147 is for treatment of APOL1 mediated focal segmental glomerulosclerosis (or FSGS) and other severe kidney disease. VX-880 is for treatment of Type 1 Diabetes and is currently in Phase 1/2 clinical trials. VX-548 is a NaV1.8 inhibitor that treats acute, neuropathic and musculoskeletal pain and is now in Phase 3. Clinical trial. It sells products to specialty pharmacies, specialty distributors, retail chains and hospitals around the world. Affinia Therapeutics, Inc., Arbor Biotechnologies, Inc., and CRISPR Therapeutics AG are some of its collaborations. ; Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., Obsidian Therapeutics, Inc., Skyhawk Therapeutics, Inc., Ribometrix, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, as well as X-Chem, Inc. Vertex Pharmacs Incorporated was established in Boston, Massachusetts in 1989.
Earnings per Share
Vertex Pharmaceuticals' trailing 12 month EPS is $10.49.
PE Ratio
Vertex Pharmaceuticals' trailing 12 months earnings to price ratio is 30.56. The purchaser of the shares is therefore investing $30.56 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 30.24%.Moving Average
Vertex Pharmaceuticals is worth more than its 50-day average moving value of $303.66, and much higher than its 200 day moving average $278.70.Growth Estimates Quarters
The company's growth estimates for the ongoing quarter and the next is 5.6% and 8.8%, respectively.Volume
Today's last reported volume for Vertex Pharmaceuticals is 789224 which is 47.48% below its average volume of 1502780.
Yearly Top and Bottom Value
Vertex Pharmaceuticals's stock is valued at $320.61 at 05:33 EST, below its 52-week high of $323.61 and way higher than its 52-week low of $203.04.
4. Euronet Worldwide (EEFT)
6.2% sales growth and 12.68% return on equity
Euronet Worldwide, Inc. provides payment and transaction processing and distribution solutions to financial institutions, agents, retailers, merchants, content providers, and individual consumers worldwide. The company's Electronic Fund Transfer Processing segment provides electronic payment solutions, including automated teller machine (ATM) cash withdrawal and deposit services, ATM network participation, outsourced ATM and point-of-sale (POS) management solutions, credit and debit card outsourcing, card issuing, and merchant acquiring services. It also offers ATM and POS currency conversion, ATM surcharge, advertising, customer relationship management, mobile top-up, bill payment, fraud management, foreign remittance and cardless payout, banknote recycling, and tax-refund services; and integrated electronic financial transaction software solutions, as well as delivers non-cash products. This segment operates a network of 42,713 ATMs and approximately 438,000 POS terminals. Its epay segment distributes and processed prepaid mobile airtime and other electronic payment products; and provides payment processing services for various prepaid products, cards, and services, as well as vouchers and physical gift fulfillment, and gift card distribution and processing services. This segment operates a network of approximately 775,000 POS terminals. The company's Money Transfer segment offers consumer-to-consumer and account-to-account money transfer, customers bill payment, check cashing, foreign currency exchange, mobile top-up, and cash management and foreign currency risk management services, as well as payment alternatives, such as money orders and prepaid debit cards. This segment operates a network of approximately 510,000 money transfer locations. The company was formerly known as Euronet Services, Inc. and changed its name to Euronet Worldwide, Inc. in August 2001. Euronet Worldwide, Inc. was founded in 1994 and is headquartered in Leawood, Kansas.
Earnings Per Share
As for profitability, Euronet Worldwide has a trailing twelve months EPS of $3.04.
PE Ratio
Euronet Worldwide has a trailing twelve months price to earnings ratio of 29.91. Meaning, the purchaser of the share is investing $29.91 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.68%.Sales Growth
Euronet Worldwide's sales growth is 7.5% for the ongoing quarter and 6.2% for the next.
5. Legacy Housing Corporation (LEGH)
6% sales growth and 18.73% return on equity
Legacy Housing Corporation builds, sells, and finances manufactured homes and tiny houses primarily in the southern United States. The company manufactures and provides for the transport of mobile homes; and offers wholesale financing to dealers and mobile home parks, as well as a range of homes, including 1 to 5 bedrooms with 1 to 3 1/2 bathrooms. It also provides floor plan or wholesale financing for independent retailers; consumer financing for its products; and financing to manufactured housing community owners that buy its products for use in their rental housing communities. The company markets its homes under the Legacy brand through a network of 100 independent and 13 company-owned retail locations, as well as direct sales to owners of manufactured home communities in 15 states in the United States. Legacy Housing Corporation was founded in 2005 and is headquartered in Bedford, Texas.
Earnings Per Share
As for profitability, Legacy Housing Corporation has a trailing twelve months EPS of $2.38.
PE Ratio
Legacy Housing Corporation has a trailing twelve months price to earnings ratio of 7.48. Meaning, the purchaser of the share is investing $7.48 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.73%.Sales Growth
Legacy Housing Corporation saw a 15.5% increase in sales for its current quarter, and an additional 6% the following.